November 2016, Volume 2, Issue 11

November 2016

Volume 2, Issue 11

This issue examines challenges related to obtaining insurance coverage for bone marrow transplants in older adults, discusses how to prepare for an educational or scientific presentation, and more.

Table of Contents

November 2016 Issue

How should I treat a patient with SCD underoing bariatric surgery?

Tuesday, November 1st, 2016
Here's how readers responded to a You Make the Call question about a patient with sickle cell disease undergoing bariatric surgery. Disclaimer: ASH does not...

Learning Your ABC

Tuesday, November 1st, 2016
In September’s Editor’s Corner, Keith Stewart, MBChB, MBA, argued that cytotoxic chemotherapy should be declared a thing of the past and imagined a future...

On Eating Bone Marrow

Tuesday, November 1st, 2016
The first time I ate bone marrow was, fittingly, shortly after I spoke on marrow failure at a conference in Milan, where osso bucco...

November 2016 Issue

2016 Lasker Award Winners, Nobel Prize in Medicine Winner, and more

Tuesday, November 1st, 2016
2016 Lasker Award Winners Announced The Albert and Mary Lasker Foundation announced the winners of its three 2016 awards. The 2016 Albert Lasker Basic Medical Research...

ASH Announces New 2017 Executive Committee Members, and more

Tuesday, November 1st, 2016
ASH Announces New 2017 Executive Committee Members On October 26, the American Society of Hematology (ASH) announced the election of four new members to its...

November 2016 Issue

Talking the Talk

Tuesday, November 1st, 2016
Presenting at a Scientific Meeting Soon? We’re Here to Help! The 58th ASH Annual Meeting is right around the corner, which means some of our...

For Transplants, Is Age Just a Number?

Tuesday, November 1st, 2016
Growing Demand, Little Coverage for Older Patients in Need of a Bone Marrow Transplant Many of the hematologic conditions that can be treated with blood and...

Pulling Back the Curtain: Vincent Ho, MD

Tuesday, November 1st, 2016
You were born in South Vietnam during the war. Could you tell us about your experiences before coming to the United States? I was born...

November 2016 Issue

How should I treat a patient with SCD underoing bariatric surgery?

Tuesday, November 1st, 2016
This month, Allison King, MD, MPH, PhD, advises on how a patient with sickle cell disease (SCD) undergoing bariatric surgery should be managed.A 33-year-old female...

The Pediatric Patient Living With Sickle Cell Disease

Tuesday, November 1st, 2016
Sickle cell disease (SCD) is the most common genetic disorder in the United States, with about 100,000 American who have the disease and another...

November 2016 Issue

For Rituximab-Refractory NHL Patients, Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival

Tuesday, November 1st, 2016
Patients with indolent non-Hodgkin lymphoma (NHL) who do not respond to regimens containing rituximab have few subsequent treatment options and generally poor outcomes. Research...
WIB_icon

Study Finds Adding Ibrutinib to Rituximab and Lenalidomide Not Justified in Frontline Setting for...

Tuesday, November 1st, 2016
Treatment with the triplet combination of ibrutinib, rituximab, and lenalidomide led to a high overall response rate (ORR) of 95 percent in patients with...

FDA Looking to Regulate Stem Cells After Clinics are Caught Marketing Them for Unapproved...

Tuesday, November 1st, 2016
A study published earlier this year in Cell Stem Cell indicated that at least 351 companies in the United States are marketing unapproved stem cell procedures at...

AACR Releases 2016 Cancer Progress Report, Touts Research Outcomes

Tuesday, November 1st, 2016
The American Association for Cancer Research (AACR) released its “Sixth Annual Cancer Progress Report,” highlighting the achievements and challenges for cancer care and research. The...

ASH Releases Statement on Congressional Funding

Tuesday, November 1st, 2016
ASH released a statement from President Charles S. Abrams, MD, congratulating Congress on the passage of a short-term resolution to fund the NIH and other federal...

Ibrutinib Submitted to FDA for Treatment of Marginal Zone Lymphoma

Tuesday, November 1st, 2016
The FDA received a supplemental new drug application (sNDA) for ibrutinib for the treatment of marginal zone lymphoma (MZL). If approved, it could become...

FDA Encourages Collaborative and Innovative Approach to Clinical Trial Designs

Tuesday, November 1st, 2016
The FDA Oncology Center of Excellence announced a series of efforts to design more efficient clinical trials. According to the FDA, “designing more efficient...

ICER Examining Suggestions from Industry and Pharmaceutical Companies on Drug Cost-Effectiveness Analyses

Tuesday, November 1st, 2016
Earlier this year, the Institute for Clinical and Economic Review (ICER) released a draft report on treatment options for MM, focusing on adults with...

NCI Collaborating With Multiple Myeloma Research Foundation to Collect Genome Data

Tuesday, November 1st, 2016
The National Cancer Institute (NCI) partnered with the Multiple Myeloma Research Foundation (MMRF) to incorporate MMRF’s genomic and clinical data into the NCI’s Genomic...

Head-to-Head Trial Finds Carfilzomib Not Superior to Bortezomib in Newly Diagnosed Patients With Myeloma

Tuesday, November 1st, 2016
In the head-to-head, phase III CLARION (Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma) study of...

FDA Grants Orphan Drug Designation for SB-FIX for Hemophilia B

Tuesday, November 1st, 2016
The FDA granted orphan drug designation to SB-FIX – a zinc finger nuclease–mediated in vivo genome-editing product – for patients with hemophilia B. SB-FIX is designed...

CAR T-Cell Therapy Induces Complete Remissions in Aggressive Non-Hodgkin Lymphoma, Now Being Assessed in...

Tuesday, November 1st, 2016
In the phase II ZUMA-1 (A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma) trial of patients with aggressive...

Vepoloxamer Does Not Meet Primary Endpoint in Phase III Study in Patients With Sickle...

Tuesday, November 1st, 2016
In the phase III EPIC (Evaluation of Purified Poloxamer 188 In Crisis) study, vepoloxamer, an investigational therapy for sickle cell disease (SCD), did...

Complete Molecular Response at Three Months: An Independent Predictor of Survival in Ph+ Acute...

Tuesday, November 1st, 2016
While monitoring minimal residual disease (MRD) is a valuable prognostic tool in certain hematologic malignancies, the prognostic significance of MRD and molecular response in...

Prothrombin Complex Concentrate Safer Than Fresh Frozen Plasma for Intracranial Hemorrhage Related to Vitamin...

Tuesday, November 1st, 2016
For patients who experience intracranial hemorrhage related to vitamin K antagonists (VKA-ICH), hematoma expansion can be a major cause of mortality. The optimal method...

Introducing the Beat AML Master Trial, and more

Tuesday, November 1st, 2016
The Beat AML Master Trial Study Design: Observational, prospective cohort study Study Start Date: November 2016 Estimated Study Completion Date: November 2023 Study Status:...
WIB_icon

Negative MRD Status Predicts Longer Progression-Free Survival and Overall Survival in Relapsed/Refractory Chronic Lymphocytic...

Tuesday, November 1st, 2016
Patients with chronic lymphocytic leukemia (CLL) who achieved a complete remission after treatment with chemoimmunotherapy may still have residual disease that could lead to...
WIB_icon

Lenalidomide Plus Cyclophosphamide and Prednisone: A Safe, Effective Option for Lenalidomide-Refractory Multiple Myeloma

Tuesday, November 1st, 2016
Patients with multiple myeloma (MM) who are refractory to lenalidomide and bortezomib have limited treatment options and poor outcomes, with a median event-free survival...
WIB_icon

Direct-Acting Antivirals: An Option for Patients With Hepatitis C Virus–Associated Lymphoma?

Tuesday, November 1st, 2016
As is the case with Epstein-Barr virus, hepatitis C virus (HCV) infection has been linked to the development of B-cell lymphoproliferative disorders, and the...

Andexanet Alfa Reduces Anti-Factor Xa Activity for Patients With Acute Major Bleeding

Tuesday, November 1st, 2016
Factor Xa (FXa) inhibitors, such as the direct oral anticoagulants rivaroxaban and apixaban, are safe and effective for the treatment of venous thromboembolism and...
WIB_icon

Evaluating Brentuximab Vedotin Plus AVD and Radiation Therapy for Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

Tuesday, November 1st, 2016
In a multicenter pilot study published in Blood, investigators reported that brentuximab vedotin plus adriamycin, vinblastine, and dacarbazine (BV + AVD) and involved-site radiation...

Nivolumab Safe and Effective for Treatment of Various Subtypes of Non-Hodgkin Lymphoma

Tuesday, November 1st, 2016
Nivolumab, a monoclonal antibody that targets programmed death-1 (PD-1) receptors on T cells, has previously been shown to produce durable responses in patients with...

November 2016 Issue

SHARE